Literature DB >> 15292665

Linkage of M5 muscarinic and alpha7-nicotinic receptor genes on 15q13 to schizophrenia.

Vincenzo De Luca1, Haoran Wang, Alessio Squassina, Greg W H Wong, John Yeomans, James L Kennedy.   

Abstract

Most antipsychotic drugs act on the forebrain by blocking dopamine receptors. In rodents, the M5 muscarinic receptor (CHRM5) is important for prolonged dopamine release. We typed polymorphisms in CHRM5 and alpha7-nicotinic receptor (CHRNA7) genes on 15q13 in 82 Canadian families having at least 1 schizophrenic patient. Using the Family-Based Association Test, we performed haplotype analysis of the 2 loci and found biased transmission in schizophrenia (z = -2.651, p = 0.008). In the families tested, the 2 cholinergic genes interacted to affect schizophrenia in combination, while neither was sufficiently alone to confer susceptibility. Our present study provided the first line of direct evidence suggesting that the CHRM5 gene combined with the CHRNA7 gene may be linked to schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292665     DOI: 10.1159/000079102

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  23 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release.

Authors:  Jacob Bendor; José E Lizardi-Ortiz; Robert I Westphalen; Markus Brandstetter; Hugh C Hemmings; David Sulzer; Marc Flajolet; Paul Greengard
Journal:  EMBO J       Date:  2010-07-27       Impact factor: 11.598

Review 3.  The antipsychotic potential of muscarinic allosteric modulation.

Authors:  Thomas M Bridges; Evan P LeBois; Corey R Hopkins; Michael R Wood; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  Drug News Perspect       Date:  2010-05

4.  Voxelwise gene-wide association study (vGeneWAS): multivariate gene-based association testing in 731 elderly subjects.

Authors:  Derrek P Hibar; Jason L Stein; Omid Kohannim; Neda Jahanshad; Andrew J Saykin; Li Shen; Sungeun Kim; Nathan Pankratz; Tatiana Foroud; Matthew J Huentelman; Steven G Potkin; Clifford R Jack; Michael W Weiner; Arthur W Toga; Paul M Thompson
Journal:  Neuroimage       Date:  2011-04-08       Impact factor: 6.556

Review 5.  Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.

Authors:  Daniel J Foster; Carrie K Jones; P Jeffrey Conn
Journal:  Discov Med       Date:  2012-12       Impact factor: 2.970

6.  M5 receptor activation produces opposing physiological outcomes in dopamine neurons depending on the receptor's location.

Authors:  Daniel J Foster; Patrick R Gentry; Jose E Lizardi-Ortiz; Thomas M Bridges; Michael R Wood; Colleen M Niswender; David Sulzer; Craig W Lindsley; Zixiu Xiang; P Jeffrey Conn
Journal:  J Neurosci       Date:  2014-02-26       Impact factor: 6.167

7.  Reversal of scopolamine-induced disruption of prepulse inhibition by clozapine in mice.

Authors:  Philipp Singer; Benjamin K Yee
Journal:  Pharmacol Biochem Behav       Date:  2011-12-21       Impact factor: 3.533

8.  Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type.

Authors:  Laura F Martin; Sherry Leonard; Mei-Hua Hall; Jason R Tregellas; Robert Freedman; Ann Olincy
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-07-05       Impact factor: 3.568

Review 9.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

10.  Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

Authors:  W Y Chan; D L McKinzie; S Bose; S N Mitchell; J M Witkin; R C Thompson; A Christopoulos; S Lazareno; N J M Birdsall; F P Bymaster; C C Felder
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.